Example: Heart Attack

Search clinical trials for: Aspirin, dipyridamole drug combination

Total 27 results

NCT04410328

Not yet recruiting

Aggrenox To Treat Acute Covid-19

Conditions: Covid19
NCT02630862

Completed

Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization

Conditions: Carotid Stenosis; Cardiovascular Disease; Atherosclerosis; Stroke
NCT02278302

Completed

Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers

Conditions: Healthy
NCT02273479

Completed

Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers

Conditions: Healthy
NCT02273492

Completed

Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects

Conditions: Healthy
NCT02273505

Completed

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

Conditions: Healthy
NCT02273518

Completed

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Conditions: Healthy
NCT02273531

Completed

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Conditions: Healthy
NCT02273544

Terminated

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Conditions: Healthy
NCT02273557

Completed

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Conditions: Healthy
NCT02269228

Completed

Tolerability of Asasantin in Healthy Female and Male Subjects

Conditions: Healthy
NCT02268773

Completed

Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers

Conditions: Healthy
NCT02262793

Completed

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

Conditions: Healthy
NCT02251184

Completed

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

Conditions: Healthy
NCT02226926

Completed

Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers

Conditions: Healthy
NCT01781611

Completed

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

Conditions: Systemic Lupus Erythematosus
NCT01455935

Unknown status

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

Conditions: Stroke
NCT01303445

Completed

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

Conditions: Healthy
NCT00738894

Completed

GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients

Conditions: Stroke; Transient Ischemic Attack
NCT00562289

Completed

Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence

Conditions: Ischemic Stroke; Patent Foramen Ovale; Atrial Septal Aneurysm; Migraine
NCT00562588

Completed

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA

Conditions: Cerebrovascular Accident
NCT00311402

Completed

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

Conditions: Cerebrovascular Accident
NCT00274586

Completed

Headache Study to Compare Aggrenox Full Dose and Reduced Dose

Conditions: Cerebrovascular Accident
NCT00223717

Completed

Treatment of Supine Hypertension in Autonomic Failure

Conditions: Hypertension
NCT00153062

Completed

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Conditions: Stroke
NCT00129038

Completed

Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients

Conditions: Coronary Arteriosclerosis
NCT00067119

Completed

Aggrenox Prevention of Access Stenosis

Conditions: Kidney Failure

Search clinical trials for: Aspirin, dipyridamole drug combination

Recent CRA jobs

Clinical Manager - Home-Based - West/Midwest

Scientist - Large Molecule HPLC ( SEC , IEX , RP )

Sr. Lab Tech/Scient Aff Spec

Sr Project Manager - Peri and Post Approval - Interventional Hematolgy / Oncology Team

Sr Project Manager - Gene Therapy / Rare Diseases

Manager Commercial Dev

CRA - Study Start Up

Associate Scientist / Scientist - Instrument Technician , GMP

Senior Regulatory Affairs Associate (MAA)

Senior Manager, IT Service Operations